louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02469493: The Effect and Mechanism of Electroacupuncture on Acute Chemotherapy-induced Nausea and Vomiting
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lung Neoplasms
Lead sponsor: Xidian University
Sponsor class: OTHER
First posted: 2015-06-11
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to compare the preventive effect of electroacupuncture and sham acupuncture on acute chemotherapy-induced nausea and vomiting and then investigate its potential mechanism by using functional Magnetic Resonance Imaging (fMRI).


Eligibility criteria: Inclusion Criteria:

* First diagnosed stage Ⅲ-Ⅳ lung cancer patients on cisplatin chemotherapy;
* Right-handed and aged 18 to 75 years;
* Karnosky performance status (KPS) ≥ 70;
* Life expectancy ≥ 6 months.

Exclusion Criteria:

* Had brain metastases or other concurrent life-threatening diseases;
* Nausea and/or vomiting were present 24h before chemotherapy treatment;
* Suffered from or had a history of gastrointestinal diseases;
* Had a history of head trauma, serious neurological or psychiatric disorders;
* Participating in other clinical trials currently;
* Had any contraindication to exposure to a high magnetic field or receive acupuncture

Primary outcomes:
measure: The scores of Rhodes Index of Nausea, Vomiting and Retching.
timeFrame: 24 hours
Secondary outcomes:
measure: Content of 5-hiaa in urine
timeFrame: 12 hours
measure: Heart Rate Variability
timeFrame: 1 hour
measure: Tachygastria percentage
timeFrame: 1 hour
measure: Dosage of antiemetic drugs
timeFrame: 24 hours
Other outcomes:
measure: Neuroimaging data
timeFrame: 24 hours
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shaanxi
Study officials:
References:
Clinical trial NCT02568293: Angioplasty + SBCV vs. Angioplasty Alone for Femoropopliteal Artery Stenosis
Official title: A Multicenter, Parallel, Blinded, Randomized Comparison of the Safety and Efficacy of Balloon Angioplasty Plus Intraluminal SBCV To Balloon Angioplasty Alone for Treatment of Stenosis or Occlusion Within the Femoropopliteal Artery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Symic Vascular
Sponsor class: INDUSTRY
Collaborators: name: Symic Biomedical, Inc.
First posted: 2015-10-05
Enrollment: 66
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare balloon angioplasty plus SBCV against balloon angioplasty alone for treatment of stenosis within the femoropopliteal artery.

Detailed description: This first-in-human study will evaluate the safety and effectiveness of a novel adjunctive therapy, SBCV, used with balloon angioplasty as compared to balloon angioplasty plus a control agent (saline) when used for the treatment of stenosis within the femoropopliteal artery. Effectiveness will be measured by late lumen loss at 24 weeks post treatment as evaluated by an independent, blinded core lab.

Eligibility criteria: Inclusion Criteria:

* Scheduled for balloon angioplasty for stenosis of femoropopliteal lesion(s)
* Rutherford Clinical Category 1-4 (claudication or critical limb ischemia)
* Lesions are ≥70% stenosis by visual estimate
* A patent inflow artery free from significant lesion
* At least one patent native outflow artery to the ankle

Exclusion Criteria:

* History of haemorrhagic stroke within 3 months of screening
* History of myocardial infarction, thrombolysis or angina within 2 weeks of screening
* Renal failure or chronic kidney disease
* Severe calcification that renders the lesion undilatable

Primary outcomes:
measure: Incidence of treatment-emergent adverse events
timeFrame: through 24 weeks
measure: Late Lumen Loss
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Royal Prince Alfred Hospital
state: New South Wales
city: Sydney
country: Australia
facility: Royal North Shore Hospital
state: New South Wales
city: Southport
country: Australia
facility: Gold Coast University Hospital
state: Queensland
city: Adelaide
country: Australia
facility: Flinders Medical Center
state: South Australia
city: Heidelberg
country: Australia
facility: Austin Health
state: Victoria
city: Melbourne
country: Australia
facility: The Alfred Hospital
state: Victoria
city: Perth
country: Australia
facility: Sir Charles Gairdner Hospital
state: Western Australia
city: Auckland
country: New Zealand
facility: Auckland City Hospital
Study officials:
References:
Clinical trial NCT01483911: ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers
Official title: Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: RSV Infection
Lead sponsor: Ablynx, a Sanofi company
Sponsor class: INDUSTRY
First posted: 2011-12-02
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: ALX-0171 is a Nanobody directed against the human respiratory syncytial virus (RSV). The purpose of this first-in-man study is to determine the safety, tolerability and pharmacokinetics (PK) of ALX-0171 after single and multiple pulmonary administrations in healthy male volunteers.


Eligibility criteria: Inclusion Criteria:

* Non-smoking healthy male volunteers, aged 18-55 years
* Good health condition, as determined by medical history, physical examination and clinical laboratory testing
* Forced expiratory volume in 1 second (FEV1) ≥ 90% of predicted value
* Diffusing capacity of the lung for CO (DLCO) ≥ 85% of predicted value
* Normal chest X-Ray (anteroposterior and lateral view)
* Minimum weight of 70.0 kg, minimum height of 1m70, body mass index between 18.0 and 30.0 kg/m²

Exclusion Criteria:

* Current smokers, or ex-smokers abstinent from tobacco for less than one year
* History or presence of atopy or pulmonary non-specific hyperreactivity
* Positive bronchial challenge test
* Symptomatic viral infection, or suspicion thereof (including rhinitis) in last 14 days prior to dosing
* Signs of active pulmonary infection or other inflammatory conditions, even in the absence of febrile episodes, in the last 14 days prior to dosing

Primary outcomes:
measure: number of treatment-emergent adverse events
timeFrame: until 1 month after last study drug administration
Secondary outcomes:
measure: plasma concentration of ALX-0171
timeFrame: from predose until 5 days after study drug administration
Other outcomes:
Locations:
city: Groningen
country: Netherlands
Study officials:
affiliation: Ablynx, a Sanofi company
name: Josefin-Beate Holz, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06503211: On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
Official title: Phase I Clinical Study on the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Sponsor class: OTHER
First posted: 2024-07-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: UTAA09 injection
Primary purpose: TREATMENT

Brief summary: The main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsed/refractory B-cell non Hodgkin's lymphoma patients. The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration.

Detailed description: Single dose, single arm trial, exploring the initial 28 day safety and efficacy of the investigational drug.

Eligibility criteria: Inclusion Criteria:

1. Subjects voluntarily participate in clinical studies;
2. ECOG score 0-1 points;
3. Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and inert lymphoma transformed into diffuse large B-cell lymphoma; CD19 and/or CD20 positivity;
4. At least one measurable tumor lesion determined according to Lugano's criteria: the longest diameter of intranodal lesions\>1.5cm, and the longest diameter of extranodal lesions\>1.0cm.

Exclusion Criteria:

1. Received other chimeric antigen receptor therapy or gene modified cell therapy before screening;
2. Subjects who were undergoing systemic steroid therapy during screening and were determined by the researchers to require long-term use of systemic steroid therapy during the treatment period (excluding inhalation or local use);
3. Any unstable heart disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \[NYHA\] classification ≥ III), and severe arrhythmia.

Primary outcomes:
measure: The incidence of dose limiting toxicity (DLT )
timeFrame: 28 days after infusion
measure: The incidence of TEAEs
timeFrame: 28 days after infusion
Secondary outcomes:
measure: ORR
timeFrame: 24 months after infusion
measure: PFS
timeFrame: 24 months after infusion
measure: OS
timeFrame: 24 months after infusion
Other outcomes:
Locations:
city: Hefei
country: China
facility: PersonGen.Anke Cellular Therapeutice Co., Ltd.
state: Anhui
Study officials:
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Xu Huang, Bachelor
role: STUDY_CHAIR
References:
Clinical trial NCT04204811: Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
Official title: A Pilot Project to Evaluate Feasibility and Patient Experience of Prehabilitation Care for Women With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Ovarian Cancer
Stage III Ovarian Cancer
Stage IV Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Carcinoma
Fallopian Tube Cancer
Keywords: Ovarian Cancer
Primary peritoneal carcinoma
Fallopian tube cancer
19-347
Memorial Sloan Kettering Cancer Center
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2019-12-19
Enrollment: 22
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.


Eligibility criteria: Inclusion Criteria:

* Subjects must be diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian rube carcinoma)
* All subjects must be enrolled within 90 days of diagnosis
* No prior treatment for ovarian carcinoma
* All subjects have agreed to a treatment plan of neoadjuvant chemotherapy and subsequent planned interval debulking surgery with an MSKCC surgeon
* Participants must be initiating treatment at Gynecologic Medical Oncology clinics at MSKCC Manhattan
* Proficiency in English in the determination of the investigators of by patient self-report

Exclusion Criteria:

* Patient under age 18
* Prior treatment for ovarian cancer
* Second opinion visit only
* Immediate surgery plan without neoadjuvant treatment
* No intended surgical plan
* Chemotherapy administration exclusively planned at MSKCC regional site
* Patient unwilling to sign consent

Primary outcomes:
measure: Median completion of participants
timeFrame: Up to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Theresa Gillis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02916511: Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Esophageal Squamous Cell Carcinoma
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2016-09-27
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate safety and 2-year local control rate for extensive clinical target volumes in postoperative radiotherapy concurrent with chemotherapy for esophageal squamous cell carcinoma.


Eligibility criteria: Inclusion Criteria:

* Joined the study voluntarily and signed informed consent form;
* Age 18-75;
* ECOG 0-2;
* Esophageal squamous cell carcinoma, radical surgery ≤ 3 months, R0 resection;
* The operative incision healed well;
* T3-4N0M0, T1-4N1-3M0 (according to AJCC2009);
* No radiotherapy, chemotherapy or other treatments pre (post) surgery;
* PS ECOG 0-2;
* Life expectancy of more than 3 months;
* Hemoglobin (Hb) ≥ 9 g/dL • WBC ≥ 3 x 109/L, Neutrophils (ANC ) ≥ 1.5 x 109/L • platelet count (Pt) ≥ 100 x 109/L • Hepatic function: ALAT and ASAT \< 2.5 x ULN, TBIL\< 1.5 x ULN • Renal function: creatinine \< 1.5 x ULN
* No immuno-deficiency;
* Use of an effective contraceptive for adults to prevent pregnancy.

Exclusion Criteria:

* Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis;
* Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years;
* Participation in other interventional clinical trials within 30 days;
* Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives;
* Drug addiction, Alcoholism or AIDS;
* Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior;
* Unsuitable to be enrolled in the trial in the opinion of the investigators.

Primary outcomes:
measure: Local control rate
timeFrame: 2 years
Secondary outcomes:
measure: overall survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan Universtiy Shanghai Cancer Center
state: Shanghai
Study officials:
References:
Clinical trial NCT00371111: To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Resistant Cystoid Macular Edema
Keywords: Resistant uveitic cystoid macular edema
intravitreal triamcinolone
intravitreal bevacizumab
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2006-09-01
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

Detailed description: This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

Eligibility criteria: Inclusion Criteria:

* Uveitic CME
* Uveitic CME refractory to routine treatment
* Vision better than 5/200 and worse than 20/50

Exclusion Criteria:

* Mono- Ocular patients
* History of vitrectomy
* Glaucoma or ocular hypertension
* History of other retinal disease that can cause macular edema
* Pregnancy
* Significant media opacity
* Vision better than 20/50

Primary outcomes:
measure: Resorbed CME in OCT
timeFrame: every 3 month
measure: Resorbed CME in clinical examination
timeFrame: Every 3 month
Secondary outcomes:
measure: need to retreatment
timeFrame: when ever needed
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Masoud Soheilian , MD
Study officials:
affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
name: Masoud Soheilian, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00373711: Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
Official title: Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Thyroid Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2006-09-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with Thyroid cancer

Brief summary: The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Detailed description: The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.

Eligibility criteria: Inclusion Criteria:- Patient at Nuclear Medicine clinic at Stanford University Medical Center

* Treated thyroid cancer.
* Detectable levels of Tg.
* Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.
* Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT
* Patients older than 18-year-old.
* Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.
* Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.
* Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them. Exclusion Criteria:- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT.
* Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.
* Pregnant women.
* Healthy volunteers.
* Patients participating in other research studies.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: Andrei Iagaru
role: PRINCIPAL_INVESTIGATOR
affiliation: Stanford University
name: Iain Ross McDougall
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00238511: An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)
Official title: An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Postherpetic Neuralgia
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2005-10-13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial was the follow-on trial to a preceeding double-blind, placebo controlled trial which included patients with at least moderate pain due to postherpetic neuralgia. It was conducted at six sites in Germany and has been clinically finalized. The patients had successfully completed the above mentioned trial in postherpetic neuralgia and, in the investigator's opinion, would benefit from long-term administration of Lacosamide. After a 1-week run-in phase the patients were uptitrated to their optimal dose and then continued into the maintenance phase. Dose adjustments were allowed throughout the trial.The change in pain was measured daily as well as interference of pain with sleep and general activity. As per protocol this trial was terminated after two years of treatment.


Eligibility criteria: Inclusion Criteria:

* Postherpetic Neuralgia

Exclusion Criteria:

* Does not benefit from long term treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Monheim
country: Germany
facility: Schwarz
Study officials:
affiliation: UCB Pharma
name: UCB Clinical Trial Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT02877511: Supervised Outdoor-Use Test For Sunscreen Products in Adults
Official title: Supervised Outdoor-Use Test For Sunscreen Products in Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-08-24
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To assess the safety of a sunscreen product under supervised outdoor-use conditions


Eligibility criteria: Inclusion Criteria:

* Subject must be healthy, males or females between 18 to 65 years of age with no medical conditions of the skin.
* Subjects must have Fitzpatrick Skin Type I, II, III or IV.
* Subjects must agree to restrict their sun exposure activities for at least five days immediately preceding participation in the study.

Exclusion Criteria:

* Subjects must not have actinic keratoses, skin cancer, psoriasis, eczema, or any other acute or chronic skin conditions.
* Subjects must not have visible erythema, blistering, or peeling that would indicate recent sunburn as determined by the baseline skin evaluation.
* Subjects must not have significantly tanned skin.

Primary outcomes:
measure: Skin response to sun exposure according to the Skin Evaluation Response Scale from 0 to 3
timeFrame: From the beginning of the study until 24 hours after study
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Petersburg
country: United States
state: Florida
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References: